This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
Top Ranked Momentum Stocks to Buy for October 9th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, October 9th
Small Caps Win in September: 5 Best ETFs & Stocks
by Sweta Killa
We highlight five small-cap ETFs and stocks that have outperformed in September. These could be excellent plays for investors should the same trends prevail.
Accelerate Diagnostics (AXDX) Jumps: Stock Rises 9.4%
by Zacks Equity Research
Accelerate Diagnostics (AXDX) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
4 Domestic Stocks to Buy on Global Economic Uncertainties
by Manaswita Ghosh Dutta
Global economic headwinds make it imperative to find suitable investments at home.
Will Cesca Therapeutics (KOOL) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
Cesca Therapeutics (KOOL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Cesca Therapeutics (KOOL) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Cesca Therapeutics (KOOL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cesca Therapeutics (KOOL) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Cesca Therapeutics (KOOL) closed at $0.30, marking a -1.68% move from the previous day.
Cesca Therapeutics (KOOL) Stock Moves -0.73%: What You Should Know
by Zacks Equity Research
In the latest trading session, Cesca Therapeutics (KOOL) closed at $0.38, marking a -0.73% move from the previous day.